| Species |
Human |
| Protein Construction |
CD93/C1q R1 (Thr22-Lys580)
Accession # Q9NPY3 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human IGFBP7, His Tag at 5μg/ml (100μl/well) on the plate can bind CD93/C1q R1 hFc Chimera, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
85 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 115-120 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CD93 has been shown critical roles in inflammatory and immune diseases. CD93 silencing increased IL-6 and TSLP, but not IL-33 levels in culture supernatants. HDM-induced asthma mice showed significant airway hyperresponsiveness and inflammation with Th2 cytokine activation, along with decreased CD93 expression in bronchial epithelial cells and lung homogenates but increased serum CD93 levels. |
| Synonyms |
C1q/MBL/SPA receptor; C1qR; C1qR(p); C1qRp; CDw93; CD93; C1QR1; MXRA4; ECSM3; dJ737E23.1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
